Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Scancell Holdings ( (GB:SCLP) ) is now available.
Scancell Holdings has secured U.S. FDA Fast Track designation for its lead cancer vaccine candidate iSCIB1+ in advanced melanoma, underscoring the therapy’s potential to improve outcomes over current checkpoint inhibitor regimens. The company reported updated Phase 2 SCOPE data showing 77% progression-free survival at 20 months in the target population when iSCIB1+ is combined with ipilimumab and nivolumab, a gain of more than 30 percentage points over standard of care.
The Fast Track status opens the door to closer FDA engagement and potentially expedited pathways such as Accelerated and Priority Review, which could shorten time to market if later-stage data are positive. Scancell plans to initiate a global registrational Phase 3 trial of iSCIB1+ in advanced melanoma in the second half of 2026, with further progression-free and early overall survival data from the ongoing Phase 2 SCOPE study expected in the first half of 2027, developments that could materially influence its competitive position in immuno-oncology and the treatment options available to melanoma patients.
Spark’s Take on SCLP Stock
According to Spark, TipRanks’ AI Analyst, SCLP is a Neutral.
The score is held back primarily by weak financials (losses, negative equity, and ongoing cash burn), partially offset by encouraging earnings-call catalysts (IND clearance and Phase III pathway) and strong technical momentum. Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on SCLP stock, click here.
More about Scancell Holdings
Scancell Holdings is a clinical-stage biotechnology company developing off-the-shelf active immunotherapies designed to generate durable, tumour-specific immune responses for cancer treatment. Its lead DNA ImmunoBody product, iSCIB1+, targets melanoma, while peptide-based Modi-1 is in Phase 2 for a range of solid tumours, and subsidiary GlyMab Therapeutics is advancing a pipeline of glycans-targeting antibodies, including assets licensed to Genmab A/S.
Average Trading Volume: 1,122,995
Technical Sentiment Signal: Buy
Current Market Cap: £132.3M
For detailed information about SCLP stock, go to TipRanks’ Stock Analysis page.